Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 10/2003

01-08-2003 | Review Article

Whole Body Pharmacokinetic Models

Author: Dr Ivan Nestorov

Published in: Clinical Pharmacokinetics | Issue 10/2003

Login to get access

Abstract

The aim of the current review is to summarise the present status of physiologically based pharmacokinetic (PBPK) modelling and its applications in drug research, and thus serve as a reference point to people interested in the methodology. The review is structured into three major sections. The first discusses the existing methodologies and techniques of PBPK model development. The second describes some of the most interesting PBPK model implementations published. The final section is devoted to a discussion of the current limitations and the possible future developments of the PBPK modelling approach. The current review is focused on papers dealing with the pharmacokinetics and/or toxicokinetics of medicinal compounds; references discussing PBPK models of environmental compounds are mentioned only if they represent considerable methodological developments or reveal interesting interpretations and/or applications.
The major conclusion of the review is that, despite its significant potential, PBPK modelling has not seen the development and implementation it deserves, especially in the drug discovery, research and development processes. The main reason for this is that the successful development and implementation of a PBPK model is seen to require the investment of significant experience, effort, time and resources. Yet, a substantial body of PBPK-related research has been accumulated that can facilitate the PBPK modelling and implementation process. What is probably lagging behind is the expertise component, where the demand for appropriately qualified staff far outreaches availability.
Footnotes
1
Use of tradenames is for product identification only and does not imply endorsement.
 
Literature
1.
Rowland M. Physiologic pharmacokinetic models and interanimal species scaling. In: Rowland M, Tucker GT, editors. Pharmacokinetics: theory and methodology. International Encyclopedia of Pharmacology and Therapeutics, Section 122. Oxford: Pergamon, 1986: 69–88
2.
Thakur AK. Model: mechanistic vs empirical. In: Resigno A, Thakur AK, editors. New trends in pharmacokinetics. New York: Plenum Press, 1991: 41–51CrossRef
3.
Rescigno A, Beck JS. The use and abuse of models. J Pharmacokinet Biopharm 1987; 15: 327–44PubMed
4.
Nestorov I, Petrov I, Hadjitodorov S, et al. Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetics relationship. Pharm Sci 1999; 1(4): 17. Available from URL: http://​www.​phamsci.​org [Accessed 2003 Jul 18]
5.
Godfrey K. Compartmental models and their application. New York: Academic Press, 1983
6.
Anderson DA. Compartmental modeling and tracer kinetics: lecture notes in biomathematics. Vol. 50. New York: SpringerVerlag, 1983CrossRef
7.
Bischoff KB. Physiological pharmacokinetics. Bull Math Biol 1986; 48: 309–22PubMed
8.
Chen HS, Gross JF. Physiologically based pharmacokinetic models for anticancer drugs. Cancer Chemother Pharmacol 1979; 2: 85–94PubMedCrossRef
9.
Gargas ML, Burgess RJ, Voisard DE, et al. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 1989; 98: 87–99PubMedCrossRef
10.
Clewell III HJ, Andersen ME. Risk assessment extrapolations and physiological modeling. Toxicol Ind Health 1985; 1: 111–31PubMed
11.
Lave T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin Pharmacokinet 1999; 36: 211–31PubMedCrossRef
12.
Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997; 29: 891–922PubMedCrossRef
13.
Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 46–58PubMed
14.
Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469–79PubMedCrossRef
15.
Haber LT, Maier A, Zhao Q, et al. Applications of mechanistic data in risk assessment: the past, present, and future. Toxicol Sci 2001; 61: 32–9PubMedCrossRef
16.
Kaneko T, Horiuchi J, Sato A. Development of a physiologically based pharmacokinetic model of organic solvent in rats. Pharmacol Res 2000; 42: 465–70PubMedCrossRef
17.
Os’Flaherty EJ. Physiologically based models of metal kinetics. Crit Rev Toxicol 1998; 28: 271–317CrossRef
18.
Bailer AJ, Dankovic DA. An introduction to the use of physiologically based pharmacokinetic models in risk assessment. Stat Methods Med Res 1997; 6: 341–58PubMedCrossRef
19.
el-Masri HA, Thomas RS, Benjamin SA, et al. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. Toxicology 1995; 105: 275–82PubMedCrossRef
20.
Yang RS, el-Masri HA, Thomas RS, et al. The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. Toxicol Lett 1995; 82–83: 497–504PubMedCrossRef
21.
Filser JG, Csanady GA, Kreuzer PE, et al. Toxicokinetic models for volatile industrial chemicals and reactive metabolites. Toxicol Lett 1995; 82–83: 357–66PubMedCrossRef
22.
Becking GC. Use of mechanistic information in risk assessment for toxic chemicals. Toxicol Lett 1995; 77: 15–24PubMedCrossRef
23.
Krewski D, Withey JR, Ku LF, et al. Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment. Environ Health Perspect 1994; 102 Suppl. 11: 37–50PubMedCrossRef
24.
Os’Flaherty EJ. Physiologically based pharmacokinetic models in developmental toxicology. Risk Anal 1994; 14: 605–11CrossRef
25.
Andersen ME, Krishnan K. Physiologically based pharmacokinetics and cancer risk assessment. Environ Health Perspect 1994; 102 Suppl. 1: 103–8PubMedCrossRef
26.
Clewell III HJ, Andersen ME. Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics. Toxicol Ind Health 1994; 10: 1–24PubMed
27.
Leung HW. Use of physiologically based pharmacokinetic models to establish biological exposure indexes. Am Ind Hyg Assoc J 1992; 53: 369–74PubMedCrossRef
28.
29.
Nestorov I, Aarons LJ, Arundel PA, et al. Lumping of wholebody physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998; 26: 21–46PubMed
30.
Baxter LT, Zhu H, Mackensen DG, et al. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995; 55: 4611–22PubMed
31.
Baxter LT, Zhu H, Mackensen DG, et al. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994; 54: 1517–28PubMed
32.
Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 2001; 18: 1190–202PubMedCrossRef
33.
Clewell III HJ, Gentry PR, Gearhart JM, et al. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol Sci 2001; 63: 160–72PubMedCrossRef
34.
Fisher JW. Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. Environ Health Perspect 2000; 108 Suppl. 2: 265–73PubMedCrossRef
35.
Lipscomb JC, Fisher JW, Confer PD, et al. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol Appl Pharmacol 1998; 152: 376–87PubMedCrossRef
36.
Fisher JW, Mahle D, Abbas R. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. Toxicol Appl Pharmacol 1998; 152: 339–59PubMedCrossRef
37.
Clewell III HJ, Andersen ME, Wills RJ, et al. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 1997; 36 (3 Pt 2): S77–85PubMedCrossRef
38.
Cong D, Doherty M, Pang KS. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 2000; 28: 224–35PubMed
39.
Clewell III HJ, Gentry PR, Covington TR, et al. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect 2000; 108 Suppl. 2: 283–305PubMedCrossRef
40.
Blakey GE, Nestorov IA, Arundel PA, et al. Quantitative structure-pharmacokinetics relationships: I. development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat. J Pharmacokinet Biopharm 1997; 25: 277–312PubMed
41.
Igari Y, Sugiyama Y, Awazu S, et al. Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat. J Pharmacokinet Biopharm 1982; 10: 53–75PubMed
42.
Igari Y, Sugiyama Y, Sawada Y, et al. Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model. J Pharmacokinet Biopharm 1983; 11: 577–93PubMed
43.
Bernareggi A, Rowland M. Physiological modeling of cyclosporine kinetics in rat and man. J Pharmacokinet Biopharm 1991; 19: 21–50PubMed
44.
Kawai R, Lemaire M, Steimer J-L, et al. Physiologically based pharmacokinetic study on a cyclosporine derivative, SDZ IMM 125. J Pharmacokinet Biopharm 1994; 22: 327–65PubMed
45.
Bjorkman S, Stanski DR, Harashima H, et al. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model. J Pharmacokinet Biopharm 1993; 21: 255–79PubMed
46.
Bjorkman S, Wada DR, Stanski DR, et al. Comparative pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models. J Pharmacokinet Biopharm 1994; 22: 381–410PubMed
47.
Peng B, Andrews J, Nestorov I, et al. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev 2001; 11: 15–27PubMedCrossRef
48.
Gerlovski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 1983; 72: 1103–29CrossRef
49.
Sato H, Sugiyama Y, Sawada Y, et al. Physiologically based pharmacokinetics of radioiodinated human beta-endorphin in rats: an application of the capillary membrane-limited model. Drug Metab Dispos 1987; 15: 540–50PubMed
50.
Tanaka C, Kawai R, Rowland M. Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dosenonlinear kinetics in rats. J Pharmacokinet Biopharm 1999; 27: 597–623PubMed
51.
Kawai R, Mathew D, Tanaka C, et al. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther 1998; 287: 457–68PubMed
52.
Naritomi Y, Terashita S, Kimura S, et al. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29: 1316–24PubMed
53.
Roberts MS, Anissimov YG. Modeling of hepatic elimination and organ distribution kinetics with the extended convection-dispersion model. J Pharmacokinet Biopharm 1999; 27: 343–82PubMed
54.
Chou CH, Aarons L, Rowland M. Optimal experimental design for precise estimation of the parameters of the axial dispersion model of hepatic elimination. J Pharmacokinet Biopharm 1998; 26: 595–615PubMed
55.
Hisaka A, Sugiyama Y. Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method. J Pharmacokinet Biopharm 1998; 26: 495–519PubMed
56.
Weiss M. Pharmacokinetics in organs of the intact body: model validation and reduction. Eur J Pharm Sci 1999; 7: 119–27PubMedCrossRef
57.
Oliver RE, Heatherington AC, Jones AF, et al. A physiologically based pharmacokinetic model incorporating dispersion principles to describe solute distribution in the perfused rat hindlimb preparation. J Pharmacokinet Biopharm 1997; 25: 389–412PubMed
58.
Roy A, Weisel CP, Lioy PJ, et al. A distributed parameter physiologically-based pharmacokinetic model for dermal and inhalation exposure to volatile organic compounds. Risk Anal 1996; 16: 147–60PubMedCrossRef
59.
Frederick CB, Bush ML, Lomax LG, et al. Application of a hybrid computational fluid dynamics and physiologically based inhalation model for interspecies dosimetry extrapolation of acidic vapors in the upper airways. Toxicol Appl Pharmacol 1998; 152: 211–31PubMedCrossRef
60.
Oliver RE, Jones AF, Rowland M. A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J Pharmacokinet Biopharm 2001; 28: 27–55
61.
Shelley ML, Harris RL, Boehlecke BA. A mathematical model of bronchial absorption of vapors in the human lung and its significance in pharmacokinetic modeling. SAR QSAR Environ Res 1996; 5: 221–53PubMedCrossRef
62.
Martonen TB. Mathematical model for the selective deposition of inhaled pharmaceuticals. J Pharm Sci 1993; 82: 1191–9PubMedCrossRef
63.
Morris JB, Hassett DN, Blanchard KT. A physiologically based pharmacokinetic model for nasal uptake and metabolism of nonreactive vapors. Toxicol Appl Pharmacol 1993; 123: 120–9PubMedCrossRef
64.
Kiriyama A, Nishiura T, Yamaji H, et al. Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor. Biopharm Drug Dispos 1999; 20: 199–205PubMedCrossRef
65.
Cox Jr LA. Reassessing benzene risks using internal doses and Monte-Carlo uncertainty analysis. Environ Health Perspect 1996; 104 Suppl. 6: 1413–29PubMedCrossRef
66.
Travis CC, Quillen JL, Arms AD. Pharmacokinetics of benzene. Toxicol Appl Pharmacol 1990; 102: 400–20PubMedCrossRef
67.
Tsuji A, Yoshikawa T, Nishide K, et al. Physiologically based pharmacokinetic model for beta-lactam antibiotics I: tissue distribution and elimination in rats. J Pharm Sci 1983; 72: 1239–52PubMedCrossRef
68.
Brown RP, Delp MD, Lindstedt SL, et al. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407–84PubMed
69.
Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–5PubMedCrossRef
70.
Kuwahira I, Gonzales NC, Heisler N, et al. Regional blood flow in conscious resting rats determined by microsphere distribution. J Appl Physiol 1993; 74: 203–10PubMed
71.
Leggert RW, Williams LR. Suggested reference values for regional blood volumes in humans. Health Phys 1989; 60: 139–54CrossRef
72.
Sato A. Confounding factors in biological monitoring of exposure to organic solvents. Int Arch Occup Environ Health 1993; 65 (1 Suppl.): S61–7PubMedCrossRef
73.
Gargas ML, Tyler TR, Sweeney LM, et al. A toxicokinetic study of inhaled ethylene glycol monomethyl ether (2-ME) and validation of a physiologically based pharmacokinetic model for the pregnant rat and human. Toxicol Appl Pharmacol 2000; 165: 53–62PubMedCrossRef
74.
Luecke RH, Wosilait WD, Pearce BA, et al. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 1994; 4: 90–103CrossRef
75.
Fisher J, Mahle D, Bankston L, et al. Lactational transfer of volatile chemicals in breast milk. Am Ind Hyg Assoc J 1997; 58: 425–31PubMedCrossRef
76.
Byczkowski JZ, Fisher JW. Lactational transfer of tetrachloroethylene in rats. Risk Anal 1994; 14: 339–49PubMedCrossRef
77.
Byczkowski JZ, Kinkead ER, Leahy HF, et al. Computer simulation of the lactational transfer of tetrachloroethylene in rats using a physiologically based model. Toxicol Appl Pharmacol 1994; 125: 228–36PubMedCrossRef
78.
Kawahara M, Sakata A, Miyashita T, et al. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci 1999; 88: 1281–7PubMedCrossRef
79.
Sasaki Y, Wagner HN. Measurement of the distribution of cardiac output in unanesthetized rats. J Appl Physiol 1971; 30: 879–84PubMed
80.
Wada DR, Bjorkman S, Ebling WF, et al. Computer simulation of the effects of alterations in blood flows and body composition on thiopental pharmacokinetics in humans. Anaesthesiology 1997; 87: 884–99CrossRef
81.
Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120: 411–20PubMedCrossRef
82.
Nestorov IA, Aarons LJ, Rowland M. Physiologically-based pharmacokinetic modelling of a homologous series of barbiturates in the rat: a sensitivity analysis. J Pharmacokin Biopharm 1997; 25: 413–47
83.
Nestorov I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1999; 27: 577–97PubMed
84.
Laughlin MH, Armstrong RB. Adrenoreceptor effects on rat muscle blood flow during treadmill exercise. J Appl Physiol 1987; 62: 1465–72PubMed
85.
Li S-G, Randall DC, Brown DR. Roles of cardiac output and peripheral resistance in mediating blood pressure response to stress in rats. Am J Physiol 1998; 274: R1065–9PubMed
86.
Calder, WA. Size, function, and life history. London: Harvard University Press, England, 1984
87.
Delp MD, Manning RO, Bruckner JV, et al. Distribution of cardiac output during diurnal changes of activity in rats. Am J Physiol 1991; 261 (5 Pt 2): H1487–93PubMed
88.
Bukowski J, Korn L, Wartenberg D. Correlated inputs in quantitative risk assessment: the effects of distributional shape. Risk Anal 1995; 15: 215–9CrossRef
89.
Jonsson F, Bois FY, Johanson G. Assessing the reliability of PBPK models using data from methyl chloride-exposed, non conjugating human subjects. Arch Toxicol 2001; 75: 189–99PubMedCrossRef
90.
Jonsson F, Johanson G. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol Appl Pharmacol 2001; 174: 99–112PubMedCrossRef
91.
Jonsson F, Johanson G. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 2001; 157: 177–93PubMedCrossRef
92.
Jonsson F, Bois F, Johanson G. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol Sci 2001; 59: 209–18PubMedCrossRef
93.
Lin JH, Sugiyama Y, Awazu S, et al. In vitro and in vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models. J Pharmacokinet Biopharm 1982; 10: 637–47PubMed
94.
Roth WL, Weber LW, Rozman KK. Incorporation of first-order uptake rate constants from simple mammillary models into blood-flow limited physiological pharmacokinetic models via extraction efficiencies. Pharm Res 1995; 12: 263–9PubMedCrossRef
95.
Hwang IY, Reardon KF, Tessari JD, et al. A gas-liquid system for enzyme kinetic studies of volatile organic chemicals: determination of enzyme kinetic constants and partition coefficients of trichloroethylene. Drug Metab Dispos 1996; 24: 377–82PubMed
96.
DeJongh J, Blaauboer BJ. Simulation of toluene kinetics in the rat by a physiologically based pharmacokinetic model with application of biotransformation parameters derived independently in vitro and in vivo. Fundam Appl Toxicol 1996; 32: 260–8PubMedCrossRef
97.
Ballard P, Leahy DE, Rowland M. Prediction of in vivo tissue distribution for in vitro data 1: experiments with markers of aqueous spaces. Pharm Res 2000; 17: 321–6CrossRef
98.
Bogaards JJ, Freidig AP, van Bladeren PJ. Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling. Chem Biol Interact 2001; 138: 247–65PubMedCrossRef
99.
Cole CE, Tran HT, Schlosser PM. Physiologically based pharmacokinetic modeling of benzene metabolism in mice through extrapolation from in vitro to in vivo. J Toxicol Environ Health A 2001; 62: 439–65PubMedCrossRef
100.
Bogaards JJ, Hissink EM, Briggs M, et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci 2000; 12: 117–24PubMedCrossRef
101.
Hissink AM, Wormhoudt LW, Sherratt PJ, et al. A physiologically-based pharmacokinetic (PB-PK) model for ethylene dibromide: relevance of extrahepatic metabolism. Food Chem Toxicol 2000; 38: 707–16PubMedCrossRef
102.
Quick DJ, Shuler ML. Use of in vitro data for construction of a physiologically based pharmacokinetic model for naphthalene in rats and mice to probe species differences. Biotechnol Prog 1999; 15: 540–55PubMedCrossRef
103.
Ploemen JP, Wormhoudt LW, Haenen GR, et al. The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide. Toxicol Appl Pharmacol 1997; 143: 56–69PubMedCrossRef
104.
Clewell III HJ. Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. Toxicol Lett 1993; 68: 101–17PubMedCrossRef
105.
Nugent LJ, Jain RK. Extravascular diffusion in normal and neoplastic tissues. Cancer Res 1984; 44: 238–44PubMed
106.
Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986; 31: 288–305PubMedCrossRef
107.
Rippe R, Haraldsson B. Fluid and protein fluxes across small and large pores in the microvasculature: application of two pore equations. Acta Physiol Scand 1987; 131: 411–28PubMedCrossRef
108.
Pastino GM, Conolly RB. Application of a physiologically based pharmacokinetic model to estimate the bioavailability of ethanol in male rats: distinction between gastric and hepatic pathways of metabolic clearance. Toxicol Sci 2000; 55: 256–65PubMedCrossRef
109.
Lilly PD, Andersen ME, Ross TM, et al. A physiologically based pharmacokinetic description of the oral uptake, tissue dosimetry, and rates of metabolism of bromodichloromethane in the male rat. Toxicol Appl Pharmacol 1998; 150: 205–17PubMedCrossRef
110.
Semino G, Lilly P, Andersen ME. A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. Toxicology 1997; 117: 25–33PubMedCrossRef
111.
Carlton LD, Pollack GM, Brouwer KL. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a ratelimiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol. J Pharm Sci 1996; 85: 473–7PubMedCrossRef
112.
Polak J, Os’Flaherty EJ, Freeman GB, et al. Evaluating lead bioavailability data by means of a physiologically based lead kinetic model. Fundam Appl Toxicol 1996; 29: 63–70PubMedCrossRef
113.
Frederick CB, Potter DW, Chang-Mateu MI, et al. A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. Toxicol Appl Pharmacol 1992; 114: 246–60PubMedCrossRef
114.
Staats DA, Fisher JW, Connolly RB. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models: a two-compartment description. Drug Metab Dispos 1991; 19: 144–8PubMed
115.
Clements JA, Nimmo WS, Heading RC, et al. A physiologically-based pharmacokinetic model for absorption of oral paracetamol in man [abstract]. J Pharm Pharmacol 1978; 30 Suppl.: 60PPubMedCrossRef
116.
Willems BA, Melnick RL, Kohn MC, et al. A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice. Toxicol Appl Pharmacol 2001; 176: 81–91PubMedCrossRef
117.
Thrall KD, Vucelick ME, Gies RA, et al. Comparative metabolism of carbon tetrachloride in rats, mice, and hamsters using gas uptake and PBPK modeling. J Toxicol Environ Health A 2000; 60: 531–48PubMedCrossRef
118.
Bogen KT, McKone TE. Linking indoor air and pharmacokinetic models to assess tetrachloroethylene risk. Risk Anal 1988; 8: 509–20PubMedCrossRef
119.
Poet TS, Corley RA, Thrall KD, et al. Assessment of the percutaneous absorption of trichloroethylene in rats and humans using MS/MS real-time breath analysis and physiologically based pharmacokinetic modeling. Toxicol Sci 2000; 56: 61–72PubMedCrossRef
120.
Thrall KD, Poet TS, Corley RA, et al. A real-time in-vivo method for studying the percutaneous absorption of volatile chemicals. Int J Occup Environ Health 2000; 6: 96–103PubMed
121.
Corley RA, Gordon SM, Wallace LA. Physiologically based pharmacokinetic modeling of the temperature-dependent dermal absorption of chloroform by humans following bath water exposures. Toxicol Sci 2000; 53: 13–23PubMedCrossRef
122.
Jepson GW, McDougal JN. Predicting vehicle effects on the dermal absorption of halogenated methanes using physiologically based modeling. Toxicol Sci 1999; 48: 180–8PubMedCrossRef
123.
Loizou GD, Jones K, Akrill P, et al. Estimation of the dermal absorption of m-xylene vapor in humans using breath sampling and physiologically based pharmacokinetic analysis. Toxicol Sci 1999; 48: 170–9PubMedCrossRef
124.
Bookout Jr RL, Quinn DW, McDougal JN. Parallel dermal subcompartments for modeling chemical absorption. SAR QSAR Environ Res 1997; 7: 259–79PubMedCrossRef
125.
Macpherson SE, Barton CN, Bronaugh RL. Use of in vitro skin penetration data and a physiologically based model to predict in vivo blood levels of benzoic acid. Toxicol Appl Pharmacol 1996; 140: 436–43PubMedCrossRef
126.
Mattie DR, Grabau JH, McDougal JN. Significance of the dermal route of exposure to risk assessment. Risk Anal 1994; 14: 277–84PubMedCrossRef
127.
McDougal JN, Jepson GW, Clewell III HJ, et al. Dermal absorption of organic chemical vapors in rats and humans. Fundam Appl Toxicol 1990; 14: 299–308PubMedCrossRef
128.
Yu LX, Lipka E, Crison JR, et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Del Rev 1996; 19: 359–76CrossRef
129.
Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996; 140: 111–8CrossRef
130.
Yu LX, Amidon GL. Characterization of small intestinal transit time distribution in humans. Int J Pharm 1998; 171: 157–63CrossRef
131.
Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186: 119–25PubMedCrossRef
132.
Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res 1999; 16: 1883–7PubMedCrossRef
133.
Williams LR, Leggert RW. Reference values for resting blood flow to organs of man. Clin Phys Physiol Meas 1989; 10: 187–217PubMedCrossRef
134.
Holt JP, Rhode EA, Kines H. Ventricular volumes and body weight in mammals. Am J Physiol 1968; 215: 704–15PubMed
135.
White L, Haines H, Adams T. Cardiac output related to body weight in small mammals. Comp Biochem Physiol 1968; 27: 559–65CrossRef
136.
Stahl WR. Scaling of respiratory variables in mammals. J Appl Physiol 1967; 22: 453–60PubMed
137.
Watanabe KH, Bois FY. Interspecies extrapolation of physiological pharmacokinetic parameter distributions. Risk Anal 1996; 16: 741–54PubMedCrossRef
138.
Ebling WF, Wada DR, Stanski DR. From piecewise to full pharmacokinetic modeling: applied to thiopental disposition in the rat. J Pharmacokinet Biopharm 1994; 22: 259–92PubMed
139.
140.
Thomas RS, Lytle WE, Keefe TJ, et al. Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (AC-SL): a computational method. Fundam Appl Toxicol 1996; 31: 19–28PubMedCrossRef
141.
Evans MV, Crank WD, Yang HM, et al. Applications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. Toxicol Appl Pharmacol 1994; 128: 36–44PubMedCrossRef
142.
Ball R, Schwartz SL. CMATRIX: software for physiologically based pharmacokinetic modeling using a symbolic matrix representation system. Comput Biol Med 1994; 24: 269–76PubMedCrossRef
143.
Krishnan K, Haddad S, Pelekis M. A simple index for representing the discrepancy between simulations of physiological pharmacokinetic models and experimental data. Toxicol Ind Health 1995; 11: 413–22PubMed
144.
Li H, Watanabe K, Auslander D, et al. Model parameter estimation and analysis: understanding parametric structure. Ann Biomed Eng 1994; 22: 97–111PubMedCrossRef
145.
Woodruff TJ, Bois FY, Auslander D, et al. Structure and parameterization of pharmacokinetic models: their impact on model predictions. Risk Anal 1992; 12: 189–201PubMedCrossRef
146.
Gallo JM, Lam FC, Perrier DG. Area method for the estimation of partition coefficients for physiological pharmacokinetic models. J Pharmacokinet Biopharm 1987; 15: 271–80PubMed
147.
Verotta D, Sheiner LB, Ebling WF, et al. A semiparametric approach to physiological flow models. J Pharmacokinet Bi-opharm 1989; 17: 463–91
148.
Chen HSG, Gross JF. Estimation of tissue to plasma partition coefficients used in physiological pharmacokinetic models. J Pharmacokinet Biopharm 1979; 7: 117–25PubMed
149.
Slob W, Janssen PH, van den Hof JM. Structural identifiability of PBPK models: practical consequences for modeling strategies and study designs. Crit Rev Toxicol 1997; 27: 261–72PubMedCrossRef
150.
Pleil JD, Lindstrom AB. Sample timing and mathematical considerations for modeling breath elimination of volatile organic compounds. Risk Anal 1998; 18: 585–602PubMedCrossRef
151.
Isukapalli SS, Roy A, Georgopoulos PG. Efficient sensitivity/uncertainty analysis using the combined stochastic response surface method and automated differentiation: application to environmental and biological systems. Risk Anal 2000; 20: 591–602PubMedCrossRef
152.
Clewell III HJ, Lee TS, Carpenter RL. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal 1994; 14: 521–31PubMedCrossRef
153.
Clewell III HJ, Jarnot BM. Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluo-robenzene. Risk Anal 1994; 14: 265–76PubMedCrossRef
154.
Hetrick DM, Jarabek AM, Travis CC. Sensitivity analysis for physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1991; 19: 1–20PubMed
155.
Varkonyi P, Bruckner JV, Gallo JM. Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations. J Pharm Sci 1995; 84: 381–4PubMedCrossRef
156.
Spear RC, Bois FY. Parameter variability and the interpretation of physiologically based pharmacokinetic modeling results. Environ Health Perspect 1994; 102 Suppl. 11: 61–6PubMedCrossRef
157.
Spear RC, Bois FY, Woodruff T, et al. Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications. Risk Anal 1991; 11: 641–54PubMedCrossRef
158.
Farrar D, Allen B, Crump K, et al. Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. Toxicol Lett 1989; 49: 371–85PubMedCrossRef
159.
Krewski D, Wang Y, Bartlett S, et al. Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. J Biopharm Stat 1995; 5: 245–71PubMedCrossRef
160.
161.
Jang JY, Droz PO, Chung HK. Uncertainties in physiologically based pharmacokinetic models caused by several input parameters. Int Arch Occup Environ Health 1999; 72: 247–54PubMedCrossRef
162.
Isukapalli SS, Roy A, Georgopoulos PG. Stochastic response surface methods (SRSMs) for uncertainty propagation: application to environmental and biological systems. Risk Anal 1998; 18: 351–63PubMedCrossRef
163.
Allen BC, Covington TR, Clewell HJ. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 1996; 111: 289–303PubMedCrossRef
164.
Hattis D, White P, Koch P. Uncertainties in pharmacokinetic modeling for perchloroethylene: II. comparison of model predictions with data for a variety of different parameters. Risk Anal 1993; 13: 599–610PubMedCrossRef
165.
Gearhart JM, Mahle DA, Greene RJ, et al. Variability of physiologically based pharmacokinetic (PBPK) model parameters and their effects on PBPK model predictions in a risk assessment for perchloroethylene (PCE). Toxicol Lett 1993; 68: 131–44PubMedCrossRef
166.
Hattis D, White P, Marmorstein L, et al. Uncertainties in pharmacokinetic modeling for perchloroethylene: I. comparison of model structure, parameters, and predictions for lowdose metabolism rates for models derived by different authors. Risk Anal 1990; 10: 449–58PubMedCrossRef
167.
Licata AC, Dekant W, Smith CE, et al. A physiologically based pharmacokinetic model for methyl tert-butyl ether in humans: implementing sensitivity and variability analyses. Toxicol Sci 2001; 62: 191–204PubMedCrossRef
168.
Clewell HJ, Gearhart JM, Gentry PR, et al. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 1999; 19: 547–58PubMed
169.
Evans MV, Andersen ME. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat. Toxicol Sci 2000; 54: 71–80PubMedCrossRef
170.
Beck BD, Mattuck RL, Bowers TS, et al. The development of a stochastic physiologically-based pharmacokinetic model for lead. Sci Total Environ 2001; 274: 15–9PubMedCrossRef
171.
Sweeney LM, Tyler TR, Kirman CR, et al. Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. Toxicol Sci 2001; 62: 124–39PubMedCrossRef
172.
Thomas RS, Bigelow PL, Keefe TJ, et al. Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am Ind Hyg Assoc J 1996; 57: 23–32PubMedCrossRef
173.
Cronin IV WJ, Oswald EJ, Shelley ML, et al. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling. Risk Anal 1995; 15: 555–65PubMedCrossRef
174.
175.
176.
Ings RMJ. Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 1990; 11: 1201–31CrossRef
177.
Ruelius HW. Extrapolation from animals to man: predictions, pitfalls and perspectives. Xenobiotica 1987; 17: 255–65PubMedCrossRef
178.
Sawada Y, Harashima H, Hanano M, et al. Prediction of the plasma concentration time courses of various drugs in humans based on data from rats. J Pharmacobiodyn 1985; 8: 757–66PubMedCrossRef
179.
Fennell TR, Brown CD. A physiologically based pharmacokinetic model for ethylene oxide in mouse, rat, and human. Toxicol Appl Pharmacol 2001; 173: 161–75PubMedCrossRef
180.
Young JF, Wosilait WD, Luecke RH. Analysis of methylmercury disposition in humans utilizing a PBPK model and animal pharmacokinetic data. J Toxicol Environ Health A 2001; 63: 19–52PubMedCrossRef
181.
Ploeger B, Mensinga T, Sips A, et al. A human physiologicallybased model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 2000; 17: 1516–25PubMedCrossRef
182.
Wang X, Santostefano MJ, DeVito MJ, et al. Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species. Toxicol Sci 2000; 56: 49–60PubMedCrossRef
183.
Chow HH. A physiologically based pharmacokinetic model of zidovudine (AZT) in the mouse: model development and scale-up to humans. J Pharm Sci 1997; 86: 1223–8PubMedCrossRef
184.
Bonate PL, Swann A, Silverman PB. Preliminary physiologically based pharmacokinetic model for cocaine in the rat: model development and scale-up to humans. J Pharm Sci 1996; 85: 878–83PubMedCrossRef
185.
Dallas CE, Chen XM, Muralidhara S, et al. Physiologically based pharmacokinetic model useful in prediction of the influence of species, dose, and exposure route on perchloroethylene pharmacokinetics. J Toxicol Environ Health 1995; 44: 301–17PubMedCrossRef
186.
Hildebrand M. Inter-species extrapolation of pharmacokinetic data of three prostacyclin-mimetics. Prostaglandins 1994; 48: 297–312PubMedCrossRef
187.
Horton VL, Higuchi MA, Rickert DE. Physiologically based pharmacokinetic model for methanol in rats, monkeys, and humans. Toxicol Appl Pharmacol 1992; 117: 26–36PubMedCrossRef
188.
Nakashima E, Yokogawa K, Ichimura F, et al. A physiologically based pharmacokinetic model for biperiden in animals and its extrapolation to humans. Chem Pharm Bull (Tokyo) 1987; 35: 718–25CrossRef
189.
Tsuji A, Nishide K, Minami H, et al. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. Drug Metab Dispos 1985; 13: 729–39PubMed
190.
Harrison LI, Gibaldi M. Physiologically based pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans. J Pharm Sci 1977; 66: 1679–83PubMedCrossRef
191.
Mann S, Droz PO, Vahter M. A physiologically based pharmacokinetic model for arsenic exposure: II. validation and application in humans. Toxicol Appl Pharmacol 1996; 140: 471–86PubMedCrossRef
192.
Poulin P, Krishnan K. A tissue composition-based algorithm for predicting tissue: air partition coefficients of organic chemicals. Toxicol Appl Pharmacol 1996; 136: 126–30PubMedCrossRef
193.
Parham FM, Kohn MC, Matthews HB, et al. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls: I. issue: blood partition coefficients. Toxicol Appl Pharmacol 1997; 144: 340–7PubMedCrossRef
194.
Pelekis M, Poulin P, Krishnan K. An approach for incorporating tissue composition data into physiologically based pharmaco-kinetic models. Toxicol Ind Health 1995; 11: 511–22PubMed
195.
Nestorov I, Aarons L, Rowland M. Quantitative structurepharmacokinetics relationships: II. mechanistically based model for the relationship between the tissue distribution parameters and the lipophilicity of the compounds. J Pharmacokinet Biopharm 1998; 26: 521–46PubMed
196.
Poulin P, Krishnan K. Molecular structure-based prediction of the partition coefficients of organic chemicals for physiological pharmacokinetic models. Toxicol Meth 1996; 6: 117–37CrossRef
197.
Balaz S, Lukacova V. A model-based dependence of the human tissue/blood partition coefficients of chemicals on lipophilicity and tissue composition. QSAR 1999; 18: 361–8
198.
Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies: 1. mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91: 129–56PubMedCrossRef
199.
Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 2001; 90: 436–47PubMedCrossRef
200.
Poulin P, Krishnan K. Molecular structure-based prediction of human abdominal skin permeability coefficients for several organic compounds. J Toxicol Environ Health A 2001; 62: 143–59PubMedCrossRef
201.
DeJongh J, Verhaar HJ, Hermens JL. A quantitative propertyproperty relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 1997; 72: 17–25PubMedCrossRef
202.
Fouchecourt MO, Beliveau M, Krishnan K. Quantitative structure-pharmacokinetic relationship modelling. Sci Total Environ 2001; 274: 125–35PubMedCrossRef
203.
Kim CS, Sandberg JA, Slikker W, et al. Quantitative exposure assessment: application of physiologically-based pharmacokinetic (PBPK) modeling of low-dose, long-term exposures of organic acid toxicant in the brain. Environ Toxicol Pharmacol 2001; 9: 153–60PubMedCrossRef
204.
Meulenberg CJ, Vijveberg HPM. Empirical relations predicting human and rat tissue: air partition coefficients of volatile organic compounds. Toxicol Appl Pharmacol 2000; 165: 206–16PubMedCrossRef
205.
Parham FM, Portier CJ. Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls: II. rates of metabolism. Toxicol Appl Pharmacol 1998; 151: 110–6PubMedCrossRef
206.
Ishizaki J, Yokogawa K, Nakashima E, et al. Relationships between the hepatic intrinsic clearance or blood cell-plasma partition coefficient in the rabbit and the lipophilicity of basic drugs. J Pharm Pharmacol 1997; 49: 768–72PubMedCrossRef
207.
Ishizaki J, Yokogawa K, Nakashima E, et al. Prediction of changes in the clinical pharmacokinetics of basic drugs on the basis of octanol-water partition coefficients. J Pharm Pharmacol 1997; 49: 762–7PubMedCrossRef
208.
Piotrovskij VK, Shvatchko EV, Trnovec T. The use of physiologically based models to simulate enantioselective differences in pharmacokinetics. Methods Find Exp Clin Pharmacol 1994 16: 263–9PubMed
209.
Melnick RL, Kohn MC. Dose-response analyses of experimental cancer data. Drug Metab Rev 2000; 32: 193–209PubMedCrossRef
210.
Chen HS, Gross JF. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 1980; 64: 31–40PubMed
211.
Chen HS, Gross JF. Clearance constants in physiologically based pharmacokinetic models. J Pharm Sci 1979; 68: 1066–7PubMedCrossRef
212.
Tsukamoto Y, Kato Y, Ura M, et al. Investigation of 5-FU disposition after oral administration of capecitabine, a tripleprodrug of 5-FU, using a physiologically based pharmacokine-tic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model. Biopharm Drug Dispos 2001; 22: 1–14PubMedCrossRef
213.
Kirman CR, Hays SM, Kedderis GL, et al. Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat. Risk Anal 2000; 20: 135–51PubMedCrossRef
214.
Zhu H, Jain RK, Baxter LT. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med 1998; 39: 65–76PubMed
215.
Zhu H, Baxter LT, Jain RK. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med 1997; 38: 731–41PubMed
216.
Devineni D, Klein-Szanto A, Gallo JM. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-bearing rats. Cancer Chemother Pharmacol 1996; 38: 499–507PubMedCrossRef
217.
Hays SM, Elswick BA, Blumenthal GM, et al. Development of a physiologically based pharmacokinetic model of 2-methoxy-ethanol and 2-methoxyacetic acid disposition in pregnant rats. Toxicol Appl Pharmacol 2000; 163: 67–74PubMedCrossRef
218.
Kawahara M, Nanbo T, Tsuji A. Physiologically based pharma-cokinetic prediction of p-phenylbenzoic acid disposition in the pregnant rat. Biopharm Drug Dispos 1998; 19: 445–53PubMedCrossRef
219.
Young JF. Physiologically-based pharmacokinetic model for pregnancy as a tool for investigation of developmental mechanisms. Comput Biol Med 1998; 28: 359–64PubMedCrossRef
220.
Ward KW, Blumenthal GM, Welsch F, et al. Development of a physiologically based pharmacokinetic model to describe the disposition of methanol in pregnant rats and mice. Toxicol Appl Pharmacol 1997; 145: 311–22PubMedCrossRef
221.
Luecke RH, Wosilait WD, Pearce BA, et al. A computer model and program for xenobiotic disposition during pregnancy. Comput Methods Programs Biomed 1997; 53: 201–24PubMedCrossRef
222.
Gray DG. A physiologically based pharmacokinetic model for methyl mercury in the pregnant rat and fetus. Toxicol Appl Pharmacol 1995; 132: 91–102PubMedCrossRef
223.
Terry KK, Elswick BA, Welsch F, et al. Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse. Toxicol Appl Pharmacol 1995; 132: 103–14PubMedCrossRef
224.
Clarke DO, Elswick BA, Welsch F, et al. Pharmacokinetics of 2-methoxyethanol and 2-methoxyacetic acid in the pregnant mouse: a physiologically based mathematical model. Toxicol Appl Pharmacol 1993; 121: 239–52PubMedCrossRef
225.
Fisher JW, Whittaker TA, Taylor DH, et al. Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 1989; 99: 395–414PubMedCrossRef
226.
Byczkowski JZ, Lipscomb JC. Physiologically based pharmacokinetic modeling of the lactational transfer of methylmercury. Risk Anal 2001; 21: 869–82PubMedCrossRef
227.
Lee SK, Ou YC, Yang RS. Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups. Toxicol Sci 2002; 65: 26–34PubMedCrossRef
228.
Jang JY, Droz PO. Ethnic differences in biological monitoring of several organic solvents: II. a simulation study with a physiologically based pharmacokinetic model. Int Arch Occup Environ Health 1997; 70: 41–50PubMedCrossRef
229.
Welsch F, Blumenthal GM, Conolly RB. Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments. Toxicol Lett 1995; 82–83: 539–47PubMedCrossRef
230.
Byczkowski JZ, Fisher JW. A computer program linking physiologically based pharmacokinetic model with cancer risk assessment for breast-fed infants. Comput Methods Programs Biomed 1995; 46: 155–63PubMedCrossRef
231.
Fisher JW, Whittaker TA, Taylor DH, et al. Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 1990; 102: 497–513PubMedCrossRef
232.
Shelley ML, Andersen ME, Fisher JW. An inhalation distribution model for the lactating mother and nursing child. Toxicol Lett 1988; 43: 23–9PubMedCrossRef
233.
Bjorkman S, Wada DR, Berling BM, et al. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001; 90: 1226–41PubMedCrossRef
234.
El-Masri HA, Portier CJ. Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice. Drug Metab Dispos 1998; 26: 585–94PubMed
235.
Krejcie TC, Avram MJ, Gentry WB, et al. A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. J Pharmacokinet Biopharm 1997; 25: 169–90PubMed
236.
Wada DR, Ward DS. Open loop control of multiple drug effects in anesthesia. IEEE Trans Biomed Eng 1995; 42: 666–77PubMedCrossRef
237.
Wada DR, Ward DS. The hybrid model: a new pharmacokinetic model for computer-controlled infusion pumps. IEEE Trans Biomed Eng 1994; 41: 134–42PubMedCrossRef
238.
Engasser JM, Sarhan F, Falcoz C, et al. Distribution, metabolism, and elimination of phenobarbital in rats: physiologically based pharmacokinetic model. J Pharm Sci 1981; 70: 1233–8PubMedCrossRef
239.
Nakajima Y, Hattori K, Shinsei M, et al. Physiologically-based pharmacokinetic analysis of grepafloxacin. Biol Pharm Bull 2000; 23: 1077–83PubMedCrossRef
240.
Manuilov KK, Navashin SM, Kuleshov SE. Use of gentamicin physiologically-based model for individual dosing. Int J Clin Pharmacol Res 1993; 13: 59–63PubMed
241.
Manuilov KK. Use of a physiologically-based pharmacokinetic model for analysis of antibiotic distribution in tissue. Int J Clin Pharmacol Ther Toxicol 1992; 30: 548–9PubMed
242.
Pollet RA, Glatz CE, Dyer DC. The pharmacokinetics of chlortetracycline orally administered to turkeys: influence of citric acid and Pasteurella multocida infection. J Pharmacokinet Biopharm 1985; 13: 243–64PubMed
243.
Weissbrod JM, Jain RK. Preliminary model for streptozocin metabolism in mice. J Pharm Sci 1980; 69: 691–4PubMedCrossRef
244.
Saijo Y, Perlaky L, Wang H, et al. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 1994; 6: 243–9PubMed
245.
Zhang R, Diasio RB, Lu Z, et al. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphoroth-ioate (gem 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 1995; 49: 929–39PubMedCrossRef
246.
Ismail M, Abd-Elsalam MA, Al-Ahaidib MS. Pharmacokinetics of 125I-labelled Walterinnesia aegyptia venom and its distribution of the venom and its toxin versus slow absorption and distribution of IgG, F(ab′)2 and F(AB) of the antivenin. Toxicon 1998; 36: 93–114PubMedCrossRef
247.
Coyne CP, Moritz JT, Fenwick BW. Inhibition of lipopolysaccharide-induced TNF-alpha production by semisyn-thetic polymyxin-B conjugated dextran. Biotechnol Ther 1994–95; 5: 137–62PubMed
248.
Covell DG, Barbet J, Holton OD, et al. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab′)2, and Fab′in mice. Cancer Res 1986; 46: 3969–78PubMed
249.
Bois F, Woodruff T, Spear R. Comparison of three physiologically based pharmacokinetic models of benzene disposition. Toxicol Appl Pharmacol 1991; 110: 79–88PubMedCrossRef
250.
Bois FY, Krowech G, Zeise L. Modeling human interindividual variability in metabolism and risk: the example of 4-aminobi-phenyl. Risk Anal 1995; 15: 205–13PubMedCrossRef
251.
252.
Bois FY. Analysis of PBPK models for risk characterization. In: Bailer AI, Maltoni C, Bailar III JC, Belpoggi F, Brazier JV, Soffritti M, editors. Uncertainty in the risk assessment of environmental and occupational hazards. Ann N Y Acad Sci 1999; 895: 317-37
253.
Bois FY, Zeise L, Tozer TN. Precision and sensitivity of pharmacokinetic models for cancer risk assessment: tetrachlorethylene in mice, rats, and humans. Toxicol Appl Pharmacol 1990; 102: 300–15PubMedCrossRef
254.
Williams PJ, Ette EI. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration s’s ‘Guidance for Industry: population pharmacokinetics s’. Clin Pharmacokinet 2000; 39: 385–95PubMedCrossRef
255.
Ette EI, Howie CA, Kelman AW, et al. Experimental design and efficient parameter estimation in preclinical pharmacokin-etic studies. Pharm Res 1995; 12: 729–37PubMedCrossRef
256.
Ette EI, Kelman AW, Howie CA, et al. Analysis of animal pharmacokinetic data: performance of the one point per animal design. J Pharmacokinet Biopharm 1995; 23: 551–66PubMed
257.
Lindstrom FT, Birkes DS. Estimation of population pharmacokinetic parameters using destructively obtained experimental data: a simulation study of the one-compartment open model. Drug Metab Rev 1984; 15: 195–264PubMedCrossRef
258.
Bernillon P, Bois FY. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ Health Perspect 2000; 108 Suppl. 5: 883–93PubMedCrossRef
259.
Bois FY. Statistical analysis of Clewell, et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 2000; 108 Suppl. 2: 307–16PubMedCrossRef
260.
Bois FY. Statistical analysis of Fisher, et al. PBPK model of trichloroethylene kinetics. Environ Health Perspect 2000; 108 Suppl. 2: 275–82PubMedCrossRef
261.
Vicini P, Pierce CH, Dills RL, et al. Individual prior information in a physiological model of 2H8-toluene kinetics: an empirical Bayes estimation strategy. Risk Anal 1999; 19: 1127–34PubMed
262.
Nestorov I, Gueorguieva I, Jones HM, et al. Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data. Drug Metab Dispos 2002; 30: 276–82PubMedCrossRef
263.
Dubois D, Prade H. Fuzzy sets and systems: theory and applications. New York: Academic Press, 1980
264.
Berkan R, Trubatch S. Fuzzy systems design principles. New York: IEEE Press, 1997
265.
Ross T. Fuzzy logic with engineering applications. New York: McGraw Hill, 1995
266.
Zimmermann H. Uncertainty modelling and fuzzy sets. In: Natke HG, Ben-Haim Y, editors. Uncertainty: models and measures. Heidelberg: Akademie-Verlag, 1997
267.
Hüllermeier E. An approach to modelling and simulation of uncertain dynamical systems. International Journal of Uncertainty, Fuzziness and Knowledge-Based Systems 1997; 5: 117–37CrossRef
268.
Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000; 25: 49–58PubMedCrossRef
269.
Norris DA, Leesman GD, Sinko PJ, et al. Development of predictive pharmacokinetic simulation models for drug discovery. J Control Release 2000; 65: 55–62PubMedCrossRef
270.
Charnick SB, Kawai R, Nedelman JR, et al. Perspectives in pharmacokinetics: physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokinet Biopharm 1995; 23: 217–29PubMed
271.
Nestorov IA. A WWW resource for physiologically based modelling in pharmacokinetics, pharmacodynamics, toxicology and risk assessment. Med Inform (Lond) 1998; 23: 193–8CrossRef
272.
Salkovich-Petrisic M, Mrzljak A, Lackovic Z. Usage of the internet pharmacology resources among European pharmacologists: a preliminary investigation. Fundam Clin Pharmacol 2001; 15: 55–60CrossRef
Metadata
Title
Whole Body Pharmacokinetic Models
Author
Dr Ivan Nestorov
Publication date
01-08-2003
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 10/2003
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342100-00002